Relmada Therapeutics (RLMD) Liabilities and Shareholders Equity (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $235.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 750.32% year-over-year to $235.4 million; the TTM figure through Mar 2026 stood at $365.4 million (up 82.45% YoY), while the FY2025 annual figure was $94.0 million, up 105.17% from the prior year.
• Liabilities and Shareholders Equity advanced to $235.4 million in Q1 2026 per RLMD's latest filing, from $94.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $235.4 million in Q1 2026 and bottomed at $14.9 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $111.5 million across 5 years, with a median of $97.6 million in 2023.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity plunged 73.3% — and 2026, when it soared 750.32%.
• Relmada Therapeutics' Liabilities and Shareholders Equity stood at $152.9 million in 2022, then tumbled by 36.2% to $97.6 million in 2023, then plunged by 53.03% to $45.8 million in 2024, then surged by 105.17% to $94.0 million in 2025, then surged by 150.38% to $235.4 million in 2026.
• Business Quant data shows RLMD's Liabilities and Shareholders Equity at $235.4 million in Q1 2026, $94.0 million in Q4 2025, and $14.9 million in Q3 2025.